Maiden preliminary results from MaxCyte, following the IPO in March, are in line with expectations. The outlook for 2016 and beyond remains confident. 35 Cell Therapy contracts are now in place (up from 30 at the year-end consequently the company is well on the way to meeting our 38 contract target for FY 2016 in this division. Drug Discovery also continues to progress well, the company now has over 50 customers in this division, some with multiple instruments, and newly signed distribution a
